CD4 and cancer: Although the importance of CD4+ T cells and MHC class II–restricted neoepitopes in cancer vaccine efficacy has been previously reported (40, 41), our current findings do not support a major role for them in mediating the antitumor effects of the LPP-mRNA vaccines.